Ewa Lech‐Marańda - Concepedia

Author

Ewa Lech‐Marańda

Instytut Hematologii i Transfuzjologi ORCID

Also Known As

E L M Lech-Maranda, E Lech-Marada, E Lech-Maranda, E Marańda, E. Lech-Maranda, E. Lech-Marańda, E. Lech‐Maranda, E. Lech‐Marańda, E.-L. Maranda, EWA LECH-MARANDA

355

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Instytut Hematologii i Transfuzjologi Medical University of Lodz The Maria Sklodowska-Curie National Research Institute of Oncology The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

Ewa Lech‐Marańda is an author at Instytut Hematologii i Transfuzjologi specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	1.5K
2	Health Sciences	8	8	238
3	Cell Biology	3	3	129
4	Natural Sciences	2	2	34
5	Biochemistry	1	1	15

Ewa Lech‐Marańda

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget, New England Journal of Medicine	2017	2K
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma Joseph M. Connors, Wojciech Jurczak, David J. Straus, New England Journal of Medicine	2017	738
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, The Lancet Phase 1/2Lymphoid NeoplasiaMedicineMalignant Blood DisorderImmunology	2021	432
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, New England Journal of Medicine	2023	190
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma Ewa Lech‐Marańda Blood	2004	184
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaMedicine5-Year UpdatePathology	2021	153
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Journal of Clinical Oncology	2021	151
Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity Tadeusz Robak, Ewa Lech‐Marańda, Anna Korycka, Current Medicinal Chemistry	2006	149
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study David J. Straus, Monika Długosz‐Danecka, Sergey Alekseev, Blood	2020	109

Page 1